Consensus Kodiak Sciences Inc.

Equities

KOD

US50015M1099

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
5.26 USD -29.40% Intraday chart for Kodiak Sciences Inc. -8.68% +73.03%

Evolution of the average Target Price on Kodiak Sciences Inc.

Price target over the last 5 years

History of analyst recommendation changes

8e9e71fdbe3e8236e7.cb6E-amfYOC5FxpPjytMNdVYZG05uFHhARmJ4bZAgPg.BcbGpvrYEY7IIit6wWYHU6wWET5K0TyiWWPxkPki970T9sXP5ukYht15Lg~9977775354d776848feb1ec035eb686b
UBS Trims Kodiak Sciences Price Target to $3 From $4, Maintains Neutral Rating MT
UBS Downgrades Kodiak Sciences to Neutral From Buy, Adjusts Price Target to $4 From $15 MT
Barclays Adjusts Price Target on Kodiak Sciences to $2 From $5, Maintains Underweight Rating MT
Chardan Downgrades Kodiak Sciences to Neutral From Buy, Withdraws Price Target MT
JPMorgan Downgrades Kodiak Sciences to Underweight From Neutral MT
Capital One Downgrades Kodiak Sciences to Equalweight From Overweight, Adjusts Price Target to $7 From $24 MT
JPMorgan Chase Adjusts Price Target on Kodiak Sciences to $10 From $12, Maintains Neutral Rating MT
Morgan Stanley Trims Price Target on Kodiak Sciences to $9 From $12, Maintains Equalweight Rating MT
Goldman Sachs Adjusts Price Target on Kodiak Sciences to $8 From $9, Maintains Neutral Rating MT
Morgan Stanley Adjusts Price Target on Kodiak Sciences to $12 From $10, Maintains Equalweight Rating MT
Chardan Research Trims Kodiak Sciences' Price Target to $18 From $19, Reiterates Buy Rating MT
Citigroup Raises Kodiak Sciences Price Target to $8 From $6, Sell Rating Reiterated MT
Truist Securities Raises Kodiak Sciences Price Target to $15 From $10, Maintains Buy Rating MT
Goldman Sachs Raises Kodiak Sciences Price Target to $9 From $5, Maintains Neutral Rating MT
Citigroup Downgrades Kodiak Sciences to Sell From Neutral; Price Target is $6 MT
Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors MT
Goldman Sachs Adjusts Price Target for Kodiak Sciences to $5 From $7, Reiterates Neutral Rating MT
Morgan Stanley Lowers Kodiak Sciences' Price Target to $10 From $12, Maintains Equalweight Rating MT
Berenberg Bank Adjusts Kodiak Sciences' Price Target to $24 From $27, Maintains Buy Rating MT
Truist Securities Adjusts Price Target on Kodiak Sciences to $10 From $35, Reiterates Buy Rating MT
Morgan Stanley Lowers Kodiak Sciences Price Target to $12 From $17, Maintains Equalweight Rating MT
UBS Lowers Kodiak Sciences Price Target to $15 From $121 as Path Forward After DAZZLE Trial Miss is 'Challenging', Reiterates Buy Rating MT
Berenberg Bank Adjusts Kodiak Sciences' Price Target to $27 From $123, Citing KSI-301 Trial Results, Maintains Buy Rating MT
Citigroup Adjusts Kodiak Sciences' Price Target to $12 From $70, Maintains Neutral Rating MT
Morgan Stanley Adjusts Kodiak Sciences' Price Target to $17 From $77, Keeps Equalweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
5.26 USD
Average target price
3.5 USD
Spread / Average Target
-33.46%
High Price Target
7 USD
Spread / Highest target
+33.08%
Low Price Target
2 USD
Spread / Lowest Target
-61.98%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Kodiak Sciences Inc.

UBS
Barclays
JPMorgan Chase
Chardan Research
Capital One Securities
Morgan Stanley
Goldman Sachs
Truist Securities
Citigroup
Berenberg Bank
BMO Capital
J.P. Morgan Chase
Roth Capital Partners
Evercore ISI
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings